New therapies in psoriasis;Nuevos tratamientos en la psoriasis

Medicina Clinica

Volumn 129, Issue 10, 2007, Pages 377-378

  Ferrándiz, Carlos ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PSORALEN; RETINOID;

CANCER; COMORBIDITY; DIABETES MELLITUS; EDITORIAL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; PHOTOTHERAPY; PREGNANCY; PSORIASIS; PUVA; RHEUMATOID ARTHRITIS; SKIN CANCER; ULTRAVIOLET B RADIATION;

EID: 35348897348     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13110216     Document Type: Editorial

References (19)

1. Ferrándiz C, Bordas X, García Patos V, Puig S, Pujol R, Smandia JA. Prevalence of psoriasis in Spain. J Eur Acad Dermatol Venereol. 2001;15:20-3.
2. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-7.
3. Ferrándiz C, García Díez A, Lizán L, Bermúdez L, Badia X. El impacto de la psoriasis en la calidad de vida relacionada con la salud. Med Clin (Barc). 2007;128:325-9.
4. Christophers E. Comorbidities in psoriasis. J Eur Acad Dermatol Venereol. 2006;20 Suppl 2:52-5.
5. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-4.
6. Gottlieb AB. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov. 2005;4:19-34.
7. Carrascosa JM, Daudén E, Hernanz Hermosa JM, Ferrándiz C. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol. 2006;20:840-5.
8. Ferrándiz C, Pujol R, García Patos V, Bordas X, Smandia JA. Psoriasis of early and late onset. A clinical and epidemiological study from Spain. J Am Acad Dermatol. 2002;46:867-73.
9. Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, et al. Clinical experience acquired with the efalizumab (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol. 2006;155:170-81.
10. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-12.
11. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-74.
12. Gottlieb AB, Hamilton T, Caro I, Kwon P, Compton PG, Leonardi CL, et al. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol. 2006;54 Suppl 1:154-63.
13. Schering-Plough. Infliximab (Remicade). Summary of product characteristics, 2005.
14. Wyeth Pharmaceuticals. Etanercept (Enbrel). Summary of products characteristics, 2004.
15. Ferrándiz C, Carrascosa JM. Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute. Br J Dermatol. 2007;156 Suppl 2:24-9.
16. Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol. 2006;54 Suppl 1:171-81.
17. Sterry W, Barker J, Boehncke W, De Bos J, Chimenti S, Christofers E, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151 Suppl 69:3-17.
18. Smith CH, Anstey JNWN, Barker AD, Burden RJG, Chalmers D, Chandler AY, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005: Br J Dermatol. 2005;153:486-97.
19. Dubertret L. Patient-based medicine. J Eur Acad Dermatol Venereol. 2006;20 Suppl 2:73-6.